However, one study with the MDM2 inhibitor MI-219, which was discontinued due to low potency, indicated that while p53 activation occurs in both healthy and cancer cells, the effect is milder in normal cells, leading only to cell cycle arrest compared with apoptosis in tumor cells [156]. Here, MDM2 is linked to cancer.